Taysha Gene Therapies Inc.
Organization details
- Legal name
- Taysha Gene Therapies Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Dallas
- Headquarters state / province
- Texas
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- TSHA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001806310
- EIN
- 84-3199512
Board of directors
-
Alison S. Long · DirectorSince 2023
-
John A. Stalfort III · DirectorSince 2023
-
Kathleen Reape · DirectorSince 2023
-
Laura Sepp-Lorenzino · DirectorSince 2023
-
Phillip B. Donenberg · DirectorSince 2023
-
Sean P. Nolan · Director · Chief Executive OfficerSince 2023
-
Sukumar Nagendran · Director · President and Head of R&DSince 2023
Chief executives
Director election results
Annual meeting of June 1, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
73.3%
-
82.6%
Board connections
5 of this board's directors also sit on 7 other boards. 6 are in the same sector.
-
Acumen Pharmaceuticals Inc. Same sectorvia John A. Stalfort III
-
Faeth Therapeutics Inc. Same sectorvia Phillip B. Donenberg
-
Lexeo Therapeutics Inc. Same sectorvia Laura Sepp-Lorenzino
-
Solid Biosciences Inc. Same sectorvia Sukumar Nagendran
-
Tectonic Therapeutic Inc. Same sectorvia Phillip B. Donenberg
- via Sean P. Nolan
-
Verrica Pharmaceuticals Inc. Same sectorvia John A. Stalfort III
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $6,658,093
- 12 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 10, 2026 | Sukumar Nagendran Director, Officer (President and Head of R&D) | Open-market sale | −200,000 | $6.24 | $1,248,000 |
| Jun 1, 2026 | John A. Stalfort III Director | Grant or award | +21,335 | — | — |
| Jun 1, 2026 | Phillip B. Donenberg Director | Grant or award | +21,335 | — | — |
| Jun 1, 2026 | Alison S. Long Director | Grant or award | +21,335 | — | — |
| Jun 1, 2026 | Laura Sepp-Lorenzino Director | Grant or award | +21,335 | — | — |
| Apr 10, 2026 | Sukumar Nagendran Director, Officer (President and Head of R&D) | Option exercise | +19,021 | $1.71 | $32,526 |
| Apr 10, 2026 | Sukumar Nagendran Director, Officer (President and Head of R&D) | Open-market sale | −200,000 | $4.46 | $892,000 |
| Feb 4, 2026 | Alam Kamran Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | −1,655 | $4.52 | $7,481 |
| Jan 26, 2026 | Sukumar Nagendran Director, Officer (President and Head of R&D) | Open-market sale | −26,918 | $4.61 | $124,092 |
| Jan 26, 2026 | Sean P. Nolan Director, Officer (Chief Executive Officer) | Open-market sale | −41,312 | $4.61 | $190,448 |
| Jan 26, 2026 | Alam Kamran Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | −23,849 | $4.61 | $109,944 |
| Jan 23, 2026 | Sukumar Nagendran Director, Officer (President and Head of R&D) | Open-market sale | −89,132 | $4.75 | $423,377 |
| Jan 23, 2026 | Sean P. Nolan Director, Officer (Chief Executive Officer) | Open-market sale | −136,789 | $4.75 | $649,748 |
| Jan 23, 2026 | Alam Kamran Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | −78,968 | $4.75 | $375,098 |
| Jan 12, 2026 | Alam Kamran Officer (CHIEF FINANCIAL OFFICER) | Grant or award | +359,000 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Taysha Gene Therapies Inc.
Who is the CEO of Taysha Gene Therapies Inc.?
Sean P. Nolan is Taysha Gene Therapies Inc.'s Chief Executive Officer.
How many directors are on Taysha Gene Therapies Inc.'s board?
Taysha Gene Therapies Inc.'s board has 7 directors: Alison S. Long, John A. Stalfort III, Kathleen Reape, Laura Sepp-Lorenzino, Phillip B. Donenberg, Sean P. Nolan and Sukumar Nagendran.
Are Taysha Gene Therapies Inc. insiders buying or selling shares?
Over the last 12 months, Taysha Gene Therapies Inc. insiders made no open-market purchases and sold $6.7 million of shares in 12 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="taysha-gene-therapies-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.